JOGO grew out of research at RUSK Institute, New York University. Several chronic residual disabilities can be addressed by harnessing neural plasticity of the brain. This key insight has driven the R&D efforts of JOGO to create several digital therapeutics to treat pelvic floor disorders, chronic pain, and neuromuscular disorders associated with stroke, Parkinson's, Cerebral Palsy, among others.
While technology and clinical evidence are critical tools, the care experienced by the patient is key to effecting good outcomes. JOGO provides unparaleled care experience via its clinics at Boston, Toronto, Chennai, Madurai, Chengalpattu, Coimbatore, and Trivandrum.
JOGO Digital Therapeutics platform is built after many decades of research. JOGO combines the best of technology components and clinical science to deliver better outcomes to patients across the world. JOGO-Gx therapeutic platform is cleared by US FDA. JOGO is a Johnson & Johnson JLABS company.
JOGO digital therapeutics uses wearable sensors and Artificial Intelligence(AI) - supported by clinically validated protocols - to provide evidence driven treatments for pain, neuromuscular, musculoskeletal and pelvic floor disorders. Digital Therapeutics is a newly classified treatment modality by the Food and Drug Administration (FDA) of the USA
JOGO digital therapeutics uses the foundational science of EMG-Biofeedback, which has been studied for more than forty years. Studies of EMG-Biofeedback have been published in prestigious medical journals such as Nature and JAMA. EMG-Biofeedback is an approved - and most importantly - highly recommended first-line treatment modality for pain, neurological and pelvic floor disorders.
Typical JOGO treatment is once a week for ten weeks, provided either in clinic or via telemedicine for most conditions. Patients with may stroke need longer treatment duration depending on the severity of the disability.